Comparing the effectiveness of two rheumatoid arthritis treatments
Analysed a nationwide, prospective real-world cohort to compare treatment response between abatacept and adalimumab and examine whether genetic differences altered their relative effectiveness.
Evidence and methods
- 342 patients included after quality control
- Clinical treatment-response outcomes
- Genetic markers and drug-level information
- Multivariable statistical modelling
- Adjustment for relevant patient and treatment factors
- Testing of treatment, genetic and interaction effects
- Careful interpretation of negative as well as positive findings
What the analysis showed
The analysis found no evidence that the relative effectiveness of the treatments differed between the genetic groups examined. The work demonstrates rigorous comparative analysis, integration of heterogeneous clinical and genetic data, and the ability to test commercially or scientifically important claims without overstating the evidence.
Read the peer-reviewed publication